Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Fukushima Medical University

Status and phase

Unknown

Phase 1

Conditions

Hepatocellular Carcinoma

Treatments

Biological: antiangiogenic paptide vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT01266707

560

Details and patient eligibility

About

The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.

Full description

It has been required to develop new treatment modalities for patients with advanced heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients. We have to assess its toxicities, clinical response and immune responsiveness.

Enrollment

9 estimated patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Unresectable or treatment-resistant patients with Hepatocellular carcinoma
Measurable disease by CT scan
ECOG performance status 0-2
Life expectancy > 3 months
Laboratory values as follows: 2,000/mm3 < WBC <15,000/mm3, Platelet counts > 75,000/mm3, Total Bilirubin < 1.5 mg/dl, Asparate transaminase < 150IU/L, Alanine transaminase < 150 IU/L, Creatinine < 3.0mg/dl
HLA-A*2402
Able and willing to give valid written informed consent

Exclusion criteria

Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception)
Brest-feeder
Active or uncontrolled infection
Steroids or immunosuppressing agent dependent status
Active or uncontrolled other malignancy
Serious or uncured wound
Decision of unsuitableness by principal investigator or physician-in charge